Summit Therapeutics faces challenges regarding its lung cancer drug, which is anticipated to be a blockbuster. While the company demonstrated a potential survival breakthrough with a novel cancer treatment showing a 16.8-month survival rate in a global lung cancer trial, questions remain over the consistency of regional data in their PD-1xVEGF studies. In comparison, Ivonescimab, combined with chemotherapy, has shown a consistent global benefit with an overall survival hazard ratio of 0.78 and improved progression-free survival in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Upcoming presentations at WCLC are expected to provide further insights, particularly regarding Ivonescimab’s performance in the Phase III HARMONi clinical trial and its enhancing effects on survival among targeted patient groups.